Context Cognitive impairment in schizophrenia is frequent, involves multiple domains, and is
enduring. Numerous recent clinical trials have suggested that second-generation
antipsychotic medications significantly enhance cognition in schizophrenia. However, none
of these studies included healthy controls undergoing repeated testing to assess the
possibility that improvements might reflect simple practice effects. Objective To report the
results on cognition of a randomized comparison of 2 widely prescribed second-generation …